News from biohaven pharmaceutical holding company ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 23, 2021, 18:40 ET Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Feb 22, 2021, 07:30 ET Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Feb 08, 2021, 07:30 ET Biohaven Provides Update On ESG Practices

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative,...

Jan 25, 2021, 07:30 ET Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative,...

Jan 18, 2021, 10:10 ET Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season

Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing ...

Jan 18, 2021, 09:00 ET Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key...

Jan 07, 2021, 07:30 ET Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest...

Jan 05, 2021, 10:00 ET Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry

Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into...

Jan 04, 2021, 07:30 ET Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial...

Dec 16, 2020, 07:30 ET Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase 3...

Dec 02, 2020, 10:05 ET Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series

Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry...

Nov 16, 2020, 07:30 ET Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Nov 11, 2020, 16:30 ET Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class ...

Nov 09, 2020, 08:00 ET Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage...

Oct 30, 2020, 18:23 ET Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Oct 14, 2020, 07:30 ET U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for ...

Sep 28, 2020, 07:00 ET BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, "Biohaven") announced today that BioShin Limited ("BioShin") its Asia-Pacific Subsidiary,...

Sep 10, 2020, 07:00 ET Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Aug 10, 2020, 07:45 ET Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Aug 07, 2020, 09:47 ET Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive...

Aug 07, 2020, 09:37 ET Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250...

Aug 05, 2020, 17:00 ET Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage...

Aug 03, 2020, 08:00 ET Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced today that the first patients were enrolled in the...

Jul 21, 2020, 07:30 ET Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has successfully completed enrollment in the M-STAR study, an...

Jul 15, 2020, 07:30 ET After Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine

Khloé Kardashian joins efforts with Biohaven Pharmaceuticals to launch the Take Back Today campaign to empower people with migraine to share their...